The short version: I'm giving Cronopharm 4 out of 10. No SA shop I've found publishes more, the newer posts follow a clear layout, and some of them are refreshingly honest about thin evidence. The big weight-loss trial numbers are mostly right too. But there are zero links to sources across 119 posts, some numbers are wrong or can't be found, the promised public lab reports aren't public, and the dosing on almost every product sits next to a line saying it isn't for self-administration.
What I looked at: cronopharm.co.za, the text of all 119 blog posts and all 79 products through the site's public data feeds, 17 posts and 9 product pages read in full, plus the FAQ, About, Quick Reads, calculator and policy pages. All on 14 October 2026.
The score, broken down
| What I marked | Score | Why |
|---|---|---|
| Is it clear? | 1 / 2 | The September posts are tidy and easy to follow. Across the site, pages contradict each other: four different storage rules for the same powder, four shipping promises, and lab reports that are “public” on one page and “on request” on another. |
| Is it useful? | 1 / 2 | Storage and mixing advice is genuinely practical. But the “side effects” and “legal access” posts are mostly a pasted shipping section, and every post ends in a buy box. |
| Are the facts right? | 1 / 2 | The headline semaglutide and retatrutide numbers hold. Several others don't: a tirzepatide range, a retatrutide claim, a TB-500 “FDA” claim and a review that doesn't seem to exist. |
| Does it show the evidence? | 0 / 2 | 0 of 119 posts link to any outside source. Only 5 even name a trial or journal. |
| Is it honest about downsides? | 1 / 2 | Most posts have a side-effects section, and some limits are stated plainly. But 1 of 35 GLP-1 posts mentions the official thyroid warning, none mentions pancreatitis, and none of the 119 warns athletes about doping rules. |
| Total | 4 / 10 | Volume and structure, without the evidence to back it. |
The supplier checks
| Check | Result | Why |
|---|---|---|
| Lab reports | Red | The About page promises a public lab report for every batch. The FAQ says they're available on request. I found none on any product page: no lab name, batch, date or verify link. |
| Claims & dosing | Red | Dose tables on 74 of 79 products and 41 posts, insulin syringes in 67 kits, injection-site advice on 31, all next to “not for self-administration”. |
| Basics | Amber | Email, WhatsApp, hours and written policies. But no street address, company name, registration or VAT number, no age limit, and every sale is final with no cancellations. |
What they got right
The most content in SA, in a clear format. 119 posts since February. The 43 newest follow the same layout every time: storage, mixing, what it's studied for, side effects, stacking, common mistakes, FAQ. Some of the practical warnings are good, like not confusing what's in the whole vial with a single amount.
Honest about thin evidence, sometimes. The BPC-157 explainer says plainly that “human clinical trials are lacking” and that most evidence comes from rats and cells. The HCG post says its use for weight loss “is not supported by mainstream evidence”. The Dihexa post flags a “limited body of published human safety data”. That's exactly what a buyer needs to hear.
The big GLP-1 numbers mostly hold. Their semaglutide figures (14.9% weight loss over 68 weeks, 86% losing at least 5%, nausea in 44%), the 20% drop in heart events from the SELECT trial, and retatrutide's 24.2% all match the published trials and labels.
What dragged it down
“Not for self-administration”, with a kit for self-administration. All 79 product pages carry a notice that the product is “not for self-administration”. Then 74 of them have a Beginner, Intermediate and Advanced dose table, 67 come with “1 × Pack of 5 insulin syringes”, 31 say to “Rotate injection sites between doses”, and almost all link a dose calculator. 41 blog posts have the same dose tables, and 74 tell readers to see a professional “before starting any protocol”. I'm not repeating their doses here.
“It is not for human or veterinary consumption, not for medical use, and not for self-administration.”
The dose tables don't always agree with their own posts either. The Dihexa post says the amounts studied are “frequently microgram-to-sub-milligram”, then its own table goes to 2 mg a day (C07, C08). And an older post is plain weight-loss sales copy for a pre-filled pen, ending in “CLICK HERE TO ORDER YOUR CAGRISEMA 20MG PEN NOW” (C19).
“Public” lab reports that aren't public. The About page says every batch ships “with a public Certificate of Analysis”. The FAQ says lab reports “are available on request” by email. Their own Quick Reads page tells buyers to “check the Certificate of Analysis”. I didn't find one on any product page, and none of the 79 product descriptions names a lab, a batch or a test date.
Numbers that don't hold up. With no links, I traced the specific claims myself:
| What they say | What I found |
|---|---|
| Tirzepatide's main trial gave “20.9-22.5%” weight loss over 72 weeks (C14) | The trial reported 15.0% to 20.9%, depending on the dose. |
| On retatrutide, “Over 50% of participants lost 25% or more of their body weight” (C15) | Not what the published trial says. Its summary reports no 25% figure, and average loss was 2.1% on placebo and 8.7% on the lowest dose. |
| “TB-500 is one of the few peptides with FDA-approved research into corneal wound healing” (C16) | Nothing was approved. The eye trials used thymosin beta-4 eye drops, not TB-500. |
| “A 2022 systematic review of GHK-Cu published in the International Journal of Molecular Sciences” (C17) | I couldn't find it. PubMed has no 2022 GHK-Cu paper in that journal. The closest is a 2018 review there, and it isn't a systematic review. |
| “research-grade peptides can be legally sourced” (C18) | No law is cited. SAHPRA's own warnings say selling or advertising unregistered medicines breaks the Medicines Act, and mention no research exemption. |
Not one link. Across 119 posts, the only links go to Cronopharm itself and WhatsApp. Five posts name a trial or a journal, and one of those journal mentions is the review above. The dose tables say they're “compiled from published protocols” without naming any.
Missing warnings. The official tirzepatide and semaglutide labels carry a boxed warning about thyroid tumours. Only 1 of their 35 GLP-1 posts mentions it, and none mentions pancreatitis. They sell BPC-157, which is on the anti-doping prohibited list, and none of the 119 posts says so.
The basics. There's an email, a WhatsApp number, hours, and written shipping, returns, privacy and terms pages. But no street address, no company name beyond “CronoPharm”, no registration or VAT number, and no age limit anywhere. “All sales on Cronopharm are final”, with no cancellations once you've ordered (C21). The storage advice for the powder comes in four versions, from “Do not refrigerate the powder” to “-20°C to -80°C” (C12, C13). The homepage testimonials come from names like “Dr. Sarah, Molecular Biology Lab, Stellenbosch”, which can't be checked (C20).
What would get them a better grade
- Link the sources. Every trial number should point to the paper or the label.
- Fix the wrong numbers: the tirzepatide range, the retatrutide 25% claim, TB-500, and the GHK-Cu review.
- Make the pages match the notice: take the dose tables, syringes and injection advice off “not for self-administration” products, or stop saying it.
- Publish the lab reports the About page promises, per batch, with the lab named and a way to check.
- Add the official warnings (thyroid, pancreatitis) to the GLP-1 posts, and a doping note where it applies.
- Publish an address and company details, and settle on one storage rule and one shipping promise.
Do that and I'll grade it again, here, in public.
Their side
Cronopharm can reply any time through this form. If they do, I'll add it here word for word.
Spotted something I got wrong? Tell me. I fix facts fast and say what changed. I don't change a grade because someone complains, only when I've got a fact wrong or the supplier changes what they publish.
Evidence log
| Ref | What they said | Where | Seen |
|---|---|---|---|
| C02 | “Consult a qualified healthcare professional before starting any protocol” | Tirz 60mg post · saved | 14 Oct 2026 |
| C03 | “1 × Pack of 5 insulin syringes” | Tirz 60mg · saved | 14 Oct 2026 |
| C04 | “Rotate injection sites between doses” | Tirz 60mg · saved | 14 Oct 2026 |
| C05 | “not for self-administration” | Tirz 60mg · saved | 14 Oct 2026 |
| C06 | Beginner, Intermediate and Advanced dose table | Tirz 60mg · saved | 14 Oct 2026 |
| C07 | “frequently microgram-to-sub-milligram” | Dihexa post · saved | 14 Oct 2026 |
| C08 | “Advanced: 2 mg daily” | Dihexa post · saved | 14 Oct 2026 |
| C09 | “a public Certificate of Analysis on every batch” | About · saved | 14 Oct 2026 |
| C10 | “Certificates of Analysis are available on request” | FAQ · saved | 14 Oct 2026 |
| C11 | “check the Certificate of Analysis” | Quick Reads · saved | 14 Oct 2026 |
| C12 | “Do not refrigerate the powder unless your protocol specifies it” | storage guide · saved | 14 Oct 2026 |
| C13 | “preferably at -20°C to -80°C” | calculator · saved | 14 Oct 2026 |
| C14 | “SURMOUNT-1: 20.9-22.5% average weight management over 72 weeks” | tirzepatide vs semaglutide · saved | 14 Oct 2026 |
| C15 | “Over 50% of participants lost 25% or more of their body weight” | retatrutide post · saved | 14 Oct 2026 |
| C16 | “FDA-approved research into corneal wound healing” | BPC-157 and TB-500 post · saved | 14 Oct 2026 |
| C17 | “A 2022 systematic review of GHK-Cu” | healthy ageing post · saved | 14 Oct 2026 |
| C18 | “research-grade peptides can be legally sourced” | legal access post · saved | 14 Oct 2026 |
| C19 | “CLICK HERE TO ORDER YOUR CAGRISEMA 20MG PEN NOW” | Cagrisema post · saved | 14 Oct 2026 |
| C20 | “Molecular Biology Lab, Stellenbosch” | home page · saved | 14 Oct 2026 |
| C21 | “All sales on Cronopharm are final” | return policy · saved | 14 Oct 2026 |
| C22 | “human clinical trials are lacking” | BPC-157 explainer · saved | 14 Oct 2026 |
Update log
- 14 Oct 2026: First published.
Sources
- Jastreboff et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 2022.
- Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. NEJM, 2023.
- Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021.
- Lincoff et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM, 2023.
- Zepbound (tirzepatide) US prescribing information, including the boxed thyroid warning.
- ClinicalTrials.gov NCT02597803: thymosin beta-4 eye drops (ARISE-1).
- Pickart and Margolina. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci, 2018.
- SAHPRA: warning about GLP-1 products sold through social media.
- USADA: BPC-157, what athletes should know about the prohibited experimental peptide.
